Brief: IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors
06/05/2025 11:51
May 6 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES ANNOUNCES US FDA IND-CLEARANCE FOR IDE849, A POTENTIAL FIRST-IN-CLASS DLL3 TOP1 ADC, FOR A PHASE 1 STUDY IN SOLID TUMORS IDEAYA BIOSCIENCES INC - TO START PHASE 1 STUDY IN U.S. BASED ON FDA GUIDANCE Source text: ID:nPn1QSZzFa Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj